Pharmacyte Biotech Inc (OTCMKTS:PMCB) has seen an explosive rise up the charts after the Company said it may have what the White House Coronavirus Task Force is looking for just as COVID-19 cases are surging across the country. According to PMCB its COVID-19 testing kits have exactly that capability. The company licensed its COVID-19 test from Hai Kang Life Corporation in Hong Kong and is currently awaiting Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). One of the key selling points for PharmaCyte’s testing kits is that they are ideally suited for the mass testing that Dr. Fauci is convinced will make a difference.
PMCB has been around for years and many longs rightly have a deep distrust for management. One cannot discount the stocks history of explosive moves especially the historic rise of 2014 back when it was NVLX. Currently at the bottom of its range and highly liquid; speculators take PMCB very seriusly here.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
Microcapdaily has been covering PMCB for years, we noted back on January 18, 2015 shortly after PMCB started trading on the OTCBB after the name and ticker changer from NVLX. We stated at the time – Pharmacyte Biotech Inc started trading on the OTCBB on January 8 after the name change from Nuvilex, Inc. The ticker symbol changed from NVLX to PMCB. The Company said that the name change is part of its transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box® technology.
To Find out the inside Scoop on PMCB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
PMCB has been around for years and was initially incorporated as eFoodSafety.com, Inc. in 1996 in Nevada. The live-cell encapsulation technology employed by Pharmacyte Biotech is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed.
Dr.Mark Rabe, chairman of the advisory board of Pharmacyte Biotech subsidiary, Medical Marijuana Sciences (MMS) summed it up perfectly when he said ”The live cell encapsulation platform employed by Nuvilex is a unique patented technology on which treatments can be developed for deadly and debilitating diseases such as cancer and diabetes. The technology has shown to be successful in the treatment of pancreatic cancer in initial clinical trials using the conventional chemotherapy drug ifosphamide. ”
Many investors in the Company view Pharmacyte Biotech Cell-in-a-Box® cell encapsulation technology as THE future of diabetes treatment and suggest the Company is a prime buy out candidate from a major such as Bayer who may be closely watching PMCB.
According to PMCB its COVID-19 test is capable of testing hundreds of people at one time using “sample pooling” or “population screening.” The ability to test hundreds at one time will allow PharmaCyte to leverage the sensitivity of the test to local, state and government agencies, communities, companies, organizations, schools, etc., to test a pool of employees to get these entities back to work while giving them the means to do continuous testing into the future, which will create a safer environment for employees to feel comfortable in the workplace.
Professor Yu said of the ability of this COVID-19 test to do pool testing, “Where large volumes of tests are required, pooling of samples for ERT-PCR testing can increase sample throughput. The pooling strategy expedites the screening process for which the accuracy can be ensured by the highly sensitive ERT-PCR test method.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $36 million market valuation PMCB has very little debt and has done a lot to clean up the balance sheet in recent years. PMCB is an exciting story developing in small caps; one cannot discount the stocks history of explosive moves especially the historic rise of 2014 back when it was NVLX. Currently at the bottom of its range and highly liquid; speculators take PMCB very seriusly here. Now that the Company has jumped on the covid.19 bandwagon, a highly succesful route for many strugging biotechs before it, anything is possible. We will be updating on PMCB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PMCB.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in PMCB either long or short and we have not been compensated for this article.